Skip to main content
Top
Published in: Journal of Clinical Immunology 7/2021

01-10-2021 | Graft-Versus-Host Disease | Original Article

Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes

Authors: Ozlem Bayram, Sule Haskologlu, Deniz Bayrakoğlu, Sevgi Kostel Bal, Candan Islamoglu, Funda Erol Cipe, Tanil Kendirli, Nazmiye Kursun, Sukru Nail Guner, Alisan Yildiran, Gunseli Bozdogan, Mutlu Yuksek, Ismail Reisli, Klara Dalva, Caner Aytekin, Kaan Boztug, Figen Dogu, Aydan Ikinciogullari

Published in: Journal of Clinical Immunology | Issue 7/2021

Login to get access

Abstract

Severe combined immunodeficiency is an inborn error of immunity characterized by impairments in the numbers and functions of T and B lymphocytes due to various genetic causes, and if it remains untreated, patients succumb to infections during the first 2 years of life.

Purpose and Methods

This study reported retrospective data from 72 infants diagnosed with SCID including their major clinical features, HSCT characteristics, and outcomes over a 20-year period (1997–2017).

Results

Sixty-one of 72 SCID patients in the study underwent HSCT from 1997 to 2017. Median ages at the time of diagnosis and transplantation were 3.5 months and 5 months, respectively. Consanguinity was present in 68% of the patients, and T − B − NK + phenotype was predominantly identified. The overall survival was 80.3% over a 20-year period. However, the patients transplanted during an active infection had a lower survival rate of 73.9% compared to 100% for patients transplanted infection-free or with a previous infection that had resolved. The survival rate was significantly higher among recipients of HLA-identical transplants (92.9%), compared to recipients of mismatched related transplants (70%). The overall survival increased from 50 (1997–2006) to 85% (2007–2017) during the last 10 years.

Conclusions

This is one of the largest single-center studies in Turkey with extensive experience about SCID patients. Early diagnosis of SCID patients before the onset of an infection and early transplantation are shown to be extremely important factors affecting the outcome and increasing the survival regardless of the donor type based on the results of this study.
Literature
1.
go back to reference Picard C, Gaspar HB, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Crow YJ, Cunningham-Rundles C, et al. International Union of Immunological Societies: Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38:96–128.CrossRef Picard C, Gaspar HB, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Crow YJ, Cunningham-Rundles C, et al. International Union of Immunological Societies: Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38:96–128.CrossRef
2.
go back to reference Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:182–94.CrossRef Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:182–94.CrossRef
3.
go back to reference Kwan A, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–38.CrossRef Kwan A, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–38.CrossRef
4.
go back to reference Kwan A, Hu D, Song M, Gomes H, Brown DR, Bourque T, Gonzalez-Espinosa D, Lin Z, Cowan MJ, Puck JM. Successful newborn screening for SCID in the Navajo Nation. Clin Immunol. 2015;158:29–34.CrossRef Kwan A, Hu D, Song M, Gomes H, Brown DR, Bourque T, Gonzalez-Espinosa D, Lin Z, Cowan MJ, Puck JM. Successful newborn screening for SCID in the Navajo Nation. Clin Immunol. 2015;158:29–34.CrossRef
5.
go back to reference Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126:602–10.CrossRef Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126:602–10.CrossRef
6.
go back to reference Pai S-Y, Logan BR, Grififith LM, Bukley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined ımmunodeficiency, 2000–2009. N Engl J Med. 2014;371:434–46.CrossRef Pai S-Y, Logan BR, Grififith LM, Bukley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined ımmunodeficiency, 2000–2009. N Engl J Med. 2014;371:434–46.CrossRef
7.
go back to reference Heimall J, Logan BR, Cowan MJ, Notarangelo LD, Griffith LM, Puck JM, et al. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017;130:2718–27.CrossRef Heimall J, Logan BR, Cowan MJ, Notarangelo LD, Griffith LM, Puck JM, et al. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017;130:2718–27.CrossRef
9.
go back to reference Yorulmaz A, Artaç H, Kara R, Keleş S, Reisli İ. Primer immün yetmezlikli 1054 olgunun retrospektif değerlendirilmesi. Astım Allerji İmmunoloji. 2008;6:127–34. Yorulmaz A, Artaç H, Kara R, Keleş S, Reisli İ. Primer immün yetmezlikli 1054 olgunun retrospektif değerlendirilmesi. Astım Allerji İmmunoloji. 2008;6:127–34.
10.
go back to reference Neven B, Leroy S, Decaluwe H, Le Deist F, Picard C, Moshous D, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immuodeficiency. Blood. 2009;113:4114–24.CrossRef Neven B, Leroy S, Decaluwe H, Le Deist F, Picard C, Moshous D, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immuodeficiency. Blood. 2009;113:4114–24.CrossRef
11.
go back to reference Ikinciogullari A, Cagdas D, Dogu F, Tugrul T, Karasu G, Haskologlu S, et al. Clinical features and HSCT outcome for SCID in Turkey. J Clin Immunol. 2019;39:316–23.CrossRef Ikinciogullari A, Cagdas D, Dogu F, Tugrul T, Karasu G, Haskologlu S, et al. Clinical features and HSCT outcome for SCID in Turkey. J Clin Immunol. 2019;39:316–23.CrossRef
12.
go back to reference Heimall J, Puck J, Buckley RH, Fleisher TA, Gennery AR, Neven B, et al. Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation (HCT) for severe combined immunodeficiency patients: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2017;23:379–87.CrossRef Heimall J, Puck J, Buckley RH, Fleisher TA, Gennery AR, Neven B, et al. Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation (HCT) for severe combined immunodeficiency patients: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2017;23:379–87.CrossRef
13.
go back to reference Grunebaum E, Mazzolari E, Porta F, Dallera D, Atkinson A, Reid B, Notarangelo LD, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA. 2006;295:508–18.CrossRef Grunebaum E, Mazzolari E, Porta F, Dallera D, Atkinson A, Reid B, Notarangelo LD, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA. 2006;295:508–18.CrossRef
14.
go back to reference Dvorack CC, Hassan A, Slatter MA, et al. Comparision of outcomes of HSCT without chemotherapy conditioning using matched sibling and unrelated donors for treatment of SCID. J Allergy Clin Immunol. 2014;134:935–43.CrossRef Dvorack CC, Hassan A, Slatter MA, et al. Comparision of outcomes of HSCT without chemotherapy conditioning using matched sibling and unrelated donors for treatment of SCID. J Allergy Clin Immunol. 2014;134:935–43.CrossRef
15.
go back to reference Shamriz O, Chandrakasan S. Update on advances in hematopoietic cell transplantation for primary ımmunodeficiency disorders. Immunol Allergy Clin N Am. 2019;39:113–28.CrossRef Shamriz O, Chandrakasan S. Update on advances in hematopoietic cell transplantation for primary ımmunodeficiency disorders. Immunol Allergy Clin N Am. 2019;39:113–28.CrossRef
16.
go back to reference Haddad E, Hoeing M. Hematopoietic stem cell transplantation for severe combined ımmunodeficiency (SCID). Front Pediatr. 2019;7:481.CrossRef Haddad E, Hoeing M. Hematopoietic stem cell transplantation for severe combined ımmunodeficiency (SCID). Front Pediatr. 2019;7:481.CrossRef
17.
go back to reference Ouederni M, Mellouli F, Khaled MB, Kaabi H, Picard C, Bejaoui M. Successful Haploidentical Stem Cell Transplantation with post-transplant cyclophosphamide in a severe combined ımmune deficiency patient: a first report. J Clin Immunol. 2016;36:437–40.CrossRef Ouederni M, Mellouli F, Khaled MB, Kaabi H, Picard C, Bejaoui M. Successful Haploidentical Stem Cell Transplantation with post-transplant cyclophosphamide in a severe combined ımmune deficiency patient: a first report. J Clin Immunol. 2016;36:437–40.CrossRef
18.
go back to reference Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014;49:999–1008.CrossRef Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014;49:999–1008.CrossRef
19.
go back to reference Haddad E, Logan BR, et al. SCID genotype and 6-month posttransplant CD+ count predict survival and immune recovery. Blood. 2018;132:1737–49.CrossRef Haddad E, Logan BR, et al. SCID genotype and 6-month posttransplant CD+ count predict survival and immune recovery. Blood. 2018;132:1737–49.CrossRef
20.
go back to reference Fazlollahi MR, Pourpak Z, Hamidieh AA, Movahedi M, Houshmand M, et al. Clinical, laboratory and molecular finding of 63 patients with severe combined ımmunodeficiency: a decade’s experience. J Investig Allergol Clin Immunol. 2017;27:299–304.CrossRef Fazlollahi MR, Pourpak Z, Hamidieh AA, Movahedi M, Houshmand M, et al. Clinical, laboratory and molecular finding of 63 patients with severe combined ımmunodeficiency: a decade’s experience. J Investig Allergol Clin Immunol. 2017;27:299–304.CrossRef
Metadata
Title
Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes
Authors
Ozlem Bayram
Sule Haskologlu
Deniz Bayrakoğlu
Sevgi Kostel Bal
Candan Islamoglu
Funda Erol Cipe
Tanil Kendirli
Nazmiye Kursun
Sukru Nail Guner
Alisan Yildiran
Gunseli Bozdogan
Mutlu Yuksek
Ismail Reisli
Klara Dalva
Caner Aytekin
Kaan Boztug
Figen Dogu
Aydan Ikinciogullari
Publication date
01-10-2021
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 7/2021
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-01062-y

Other articles of this Issue 7/2021

Journal of Clinical Immunology 7/2021 Go to the issue